Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GD2-J1: Dinutuximab + temozolomide + irinotecan + filgrastim in recurrent or refractory high-risk neuroblastoma
jRCT2051250095Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of dinutuximab in neuroblastoma, sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Response rate based on best overall response. Started Oct 2025; status: recruiting.
02
Drugs
dinutuximab
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on jRCT2051250095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250095.